XEN1101 for Major Depressive Disorder

Part of paid clinical trials in New York, New York.

Sponsor
James Murrough
Study ID
NCT04827901
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • XEN1101 — DRUG
    two 10 mg capsules
  • Placebo — DRUG
    matching placebo

Study Details

This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).

Key Dates

Start date
Oct 19, 2021
Status verified
Mar 2025
Primary completion
Oct 3, 2024
Completion
Nov 7, 2024

Study Design

Enrollment
44 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: XEN1101
    Subjects will take two 10 mg capsules of XEN1101 daily for 8 weeks for a total daily dose of 20 mg.
  • Placebo Comparator: Placebo
    Subjects will take a matching placebo daily for eight weeks.

Primary Outcome Measure

Change in activation within the reward circuit by fMRI [ Time Frame: Baseline (week 0), End of treatment (week 8) ]

Locations (2)

FacilityCityStateZIPSite coordinators
Icahn School of Medicine at Mount SinaiNew YorkNew York10029-
Baylor College of MedicineHoustonTexas77030-

Find similar trials in New York, NY

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
Icahn School of Medicine at Mount Sinai· New York, NYBaylor College of Medicine· Houston, TX

Related Studies